liveattenu
vaccin
lav
repres
one
import
medic
innov
human
histori
past
three
centuri
lav
save
hundr
million
live
continu
mani
decad
come
interestingli
success
lav
smallpox
vaccin
measl
vaccin
yellow
fever
vaccin
isol
andor
develop
pure
empir
manner
without
understand
immunolog
mechan
trigger
today
mechan
govern
potent
lav
immunogen
longterm
induc
protect
immun
continu
elus
therefor
hamper
ration
design
innov
vaccin
strategi
seriou
roadblock
understand
lavinduc
immun
lack
suitabl
costeffect
anim
model
accur
mimic
human
immun
respons
last
two
decad
humanimmun
system
mice
mice
ie
mice
engraft
compon
human
immun
system
instrument
investig
lifecycl
immun
respons
multipl
humantrop
pathogen
howev
use
lav
research
remain
limit
discuss
strong
potenti
lav
tool
enhanc
understand
human
immun
review
past
current
futur
contribut
mice
endeavor
liveattenu
vaccin
lav
save
million
live
continu
prove
one
import
invent
modern
medic
histori
smallpox
success
erad
use
closelyrel
vaccinia
viru
live
measl
vaccin
avert
estim
million
death
immunogen
lav
superior
vaccin
type
inactiv
subunit
toxoid
vaccin
may
requir
addit
dose
adjuv
achiev
suffici
immun
tabl
contrast
singl
dose
yellow
fever
vaccin
provid
protect
diseas
least
ten
year
concern
remain
abil
lav
revert
toward
wildtyp
genotyp
human
advers
effect
risk
associ
vaccin
remain
low
clearli
outweigh
health
benefit
provid
global
scale
recent
year
alarm
episod
pathogen
emerg
licens
vaccin
ebola
lassa
zika
viru
wit
addit
emerg
potenti
current
neglect
pathogen
powassan
viru
eastern
equin
enceph
viru
strongli
highlight
global
need
better
prepared
futur
epidem
primari
limit
develop
innov
vaccin
today
tomorrow
challeng
infecti
diseas
inabl
understand
molecular
basi
current
lav
attenu
immunogen
mainli
empir
natur
develop
tradit
lav
attenu
achiev
either
serial
passag
virul
pathogen
isol
close
relat
viru
bacterium
produc
mild
diseas
human
cowpox
smallpox
vaccin
mean
exist
lav
directli
correl
capac
parent
common
ancestor
strain
evolv
adapt
novel
host
environ
therefor
lav
attenu
tie
stochast
evolut
stori
gener
yellow
fever
vaccin
strain
strongli
support
reason
isol
serial
passag
virul
yellow
fever
viru
yfv
strain
mous
chicken
embryo
tissu
despit
sever
attempt
repeat
process
could
isol
qualiti
includ
immunogen
reactogen
safeti
stabil
vaccin
type
compar
immunogen
liveattenu
vaccin
lav
superior
vaccin
type
although
reactogen
although
risk
extrem
low
lav
potenti
revert
virul
phenotyp
therefor
stabil
lower
inactiv
subunit
toxoid
vaccin
reaction
vaccin
type
may
also
occur
risk
lower
lav
high
moder
low
major
roadblock
quest
understand
mechan
lav
attenu
immunogen
absolut
need
studi
humanspecif
immun
respons
vivo
control
experiment
set
studi
lav
respons
cohort
voluntari
human
vaccine
peripher
blood
readili
assess
yet
tissu
site
infect
secondari
lymphoid
organ
immun
respons
prime
addit
precis
pinpoint
attenu
mechan
lav
import
perform
direct
comparison
immun
respons
induc
lav
virul
counterpart
howev
comparison
well
genet
manipul
immun
system
remain
ethic
imposs
human
patient
cohort
therefor
understand
lav
attenu
immunogen
fulli
reli
upon
identif
costeffect
easili
access
anim
model
accur
recapitul
human
immun
respons
upon
vaccin
human
mice
immunodefici
mice
harbor
human
tissu
andor
gene
emerg
viabl
preclin
model
model
human
biolog
process
diseas
mice
engraft
human
immun
system
mice
compon
notabl
instrument
studi
infecti
cycl
humantrop
bacteria
virus
vivo
understand
pathogen
interact
human
immun
system
howev
contribut
mice
lav
research
remain
limit
comparison
model
system
human
model
nonhuman
primat
nhp
model
mainli
convent
mice
harbor
import
limit
accur
model
lavinduc
immun
limit
human
hematopoiesi
improp
immun
prime
hamper
adapt
respons
past
five
year
novel
mice
develop
demonstr
superior
abil
mount
potent
innat
adapt
immun
respons
immunogen
pathogen
emerg
model
futur
one
come
offer
unpreced
opportun
better
understand
lav
interact
human
immun
system
time
space
site
infect
secondari
lymphoid
tissu
review
encompass
past
current
futur
applic
mice
elucid
molecular
mechan
govern
lav
attenu
immunogen
first
discuss
empir
develop
sever
histor
import
lav
posit
impact
global
human
health
review
molecular
mechan
suspect
underli
attenu
next
provid
overview
past
current
mous
model
explor
contribut
mice
understand
lav
attenu
immunogen
final
identifi
shortcom
associ
model
describ
current
futur
effort
refin
mice
model
open
avenu
better
understand
lavinduc
immun
year
lav
serv
invalu
tool
control
andor
erad
infecti
diseas
idea
infect
live
pathogen
confer
protect
deadli
infecti
diseas
employ
throughout
histori
procedur
variol
howev
end
centuri
idea
popular
edward
jenner
demonstr
inocul
cowpox
viru
produc
mild
ill
human
provid
immun
smallpox
deadli
diseas
induc
close
relat
viru
variola
viru
discoveri
jenner
promot
concept
liveattenu
vaccin
gener
concept
vaccin
well
idea
would
save
hundr
million
live
follow
centuri
research
loui
pasteur
chicken
cholera
anthrax
rabi
introduc
concept
lav
could
gener
attenu
deadli
pathogen
exposur
heat
oxygen
earli
centuri
serial
passag
pathogen
specif
media
also
found
effect
way
attenu
pathogen
gener
lav
tuberculosi
bacil
bcg
vaccin
first
vaccin
attenu
serial
passag
formul
repeat
subcultur
mycobacterium
bovi
bacterium
respons
bovin
tuberculosi
gener
bcg
vaccin
therefor
success
integr
vaccin
concept
describ
jenner
pasteur
made
attenu
pathogen
relat
bacterium
viru
respons
diseas
bcg
vaccin
henc
repres
could
consid
second
categori
lav
pentaval
rotaviru
vaccin
anoth
lav
categori
contain
combin
attenu
human
bovin
rotaviru
strain
advent
pathogen
attenu
serial
passag
brought
forth
predomin
categori
lav
made
directli
attenu
caus
pathogen
diseas
serial
passag
perform
anim
host
embryon
egg
eventu
tissu
cultur
notabl
establish
lav
gener
way
yellow
fever
polioviru
measl
mump
rubella
typhoid
varicella
zoster
vaccin
lav
undeni
repres
effect
class
vaccin
ever
develop
base
success
past
lav
sever
lav
candid
target
challeng
pathogen
dengu
viru
japanes
enceph
viru
west
nile
viru
zika
viru
sar
malaria
ebola
viru
design
evalu
instanc
respons
ebola
viru
diseas
outbreak
africa
recombin
vesicular
stomat
viru
vsv
express
envelop
glycoprotein
ebola
viru
gener
vsvebov
vsv
induc
asymptomat
infect
human
caus
mild
transient
ill
vaccin
demonstr
safeti
immunogen
multipl
phase
iiiii
clinic
trial
unlik
type
vaccin
lav
carri
potent
immunogen
epitop
abil
replic
highli
tune
rate
host
therefor
effect
reli
primarili
upon
fine
control
viru
abil
replic
lav
replic
enough
immunogen
epitop
spread
activ
potent
immun
respons
limit
stabl
enough
rate
prevent
advers
effect
genet
revers
toward
wildtyp
phenotyp
well
allow
subsequ
immun
control
infect
tabl
method
establish
lav
gener
use
relat
pathogen
attenu
relat
pathogen
attenu
caus
agent
diseas
empir
conduct
without
knowledg
immunolog
mechan
play
lav
infect
specif
mutat
viral
bacteri
genom
like
translat
differenti
hostpathogen
interact
clearli
associ
pathogen
attenu
howev
natur
specif
hostlav
interact
trigger
potent
immun
respons
remain
mostli
unknown
emerg
new
infecti
diseas
minim
advers
reaction
lav
revers
wildtyp
strain
shorttrack
vaccin
product
method
provis
immun
option
immunocompromis
individu
reason
research
mechan
govern
lav
attenu
still
remain
critic
import
today
despit
develop
potenti
promis
lav
candid
past
two
decad
fight
mani
challeng
infecti
diseas
see
exampl
limit
number
actual
licens
far
suggest
novel
ration
approach
need
design
potent
andor
safer
lav
futur
current
establish
lav
repres
formid
sourc
inform
first
section
review
histor
develop
global
impact
establish
lav
discuss
attenu
mechan
identifi
vaccin
smallpox
deadli
diseas
plagu
human
thousand
year
eventu
erad
diseas
caus
viru
variola
orthopoviru
genu
poxviru
famili
case
fatal
rate
variol
infect
materi
smallpox
pustul
scab
practic
china
india
thousand
year
introduct
europ
although
variol
safer
contract
smallpox
chanc
mortal
even
execut
correctli
commonli
known
contract
cowpox
zoonot
poxviru
close
relat
variola
induc
mild
diseas
human
contract
smallpox
deliber
inocul
viru
popular
experi
edward
jenner
publish
jenner
find
summon
wave
enthusiasm
would
eventu
term
vaccin
issu
use
cowpox
lav
includ
bacteri
contamin
unmeasur
potenc
caus
vaccin
support
wane
earli
vaccin
made
lymph
infect
calv
propag
vaccine
armtoarm
transfer
consid
unsaf
spread
bloodborn
diseas
viru
close
relat
cowpox
variola
known
vaccinia
took
place
cowpox
sourc
smallpox
lav
may
also
contamin
result
vari
method
viru
passag
despit
initi
setback
smallpox
vaccin
vital
scientif
advanc
made
centuri
includ
limit
vaccin
bacteri
count
ie
nonpathogen
bacteri
contamin
vaccin
prepar
determin
requir
potenc
induc
smallpox
immun
introduct
seed
lot
system
world
health
organ
creat
vaccin
suppli
greater
consist
temperatur
stabil
freez
dri
invent
bifurc
needl
allow
vaccin
transport
greater
distanc
administ
effici
lav
enhanc
along
lack
anim
reservoir
diseas
made
smallpox
prime
candid
global
erad
reason
world
health
organ
initi
smallpox
erad
program
mani
vaccin
strain
use
program
commonli
use
lav
dryvax
deriv
nycbh
strain
elstre
lister
strain
tiantan
templ
heaven
strain
global
effort
aid
effect
lav
smallpox
erad
vaccinia
lav
potent
reactogen
complic
uncommon
seriou
also
unsuit
immunocompromis
individu
would
risk
case
epidem
light
recent
outbreak
known
novel
zoonot
poxvirus
potenti
use
smallpox
bioterror
secondgener
vaccin
deriv
origin
vaccinia
strain
tissu
cultur
lav
made
highli
attenu
modifi
vaccinia
ankara
strain
understand
interact
vaccinia
lav
human
immun
system
major
part
develop
new
lav
combat
orthpoxvirus
futur
follow
jenner
success
smallpox
vaccin
loui
pasteur
made
stride
initi
novel
gener
lav
advanc
attenu
weaken
pathogen
respons
diseas
find
cultur
pasteurella
multocida
bacterium
chicken
cholera
attenu
left
expos
air
pasteur
procur
vaccin
proceed
produc
anthrax
vaccin
anim
whose
etiolog
agent
discov
robert
koch
pasteur
contribut
human
lav
came
fruition
work
rabi
attenu
though
dri
spinal
cord
infect
rabbit
regimen
inocul
progress
less
dri
virul
sampl
rabi
could
prevent
treat
pasteur
attenu
rabi
vaccin
success
administ
human
patient
establish
first
truli
attenu
human
lav
lav
incorpor
wisdom
jenner
pasteur
research
product
offer
protect
one
deadliest
pathogen
exist
tuberculosi
tb
bacteri
infect
caus
mycobacterium
tuberculosi
bacteria
caus
death
infecti
pathogen
although
treatment
prevent
method
exist
estim
billion
individu
current
infect
tuberculosi
develop
activ
tb
transmit
bacteria
individu
year
therefor
vaccin
tb
still
remain
essenti
contain
infecti
diseas
today
licens
tb
vaccin
avail
bacil
bcg
lav
tuberculosi
first
identifi
robert
koch
although
bacterium
use
bcg
lav
mycobacterium
bovi
pathogen
respons
bovin
tuberculosi
one
equal
virul
human
attenu
bovi
achiev
albert
calmett
camil
institut
pasteur
subcultur
isol
bovi
media
contain
potato
glycerol
beef
bile
year
total
serial
passag
attenu
bcg
vaccin
success
use
infant
apart
tuberculosi
contamin
result
disast
kill
infant
infect
addit
infant
vaccin
bcg
administr
becam
widespread
without
ill
effect
multipl
strain
thu
develop
apprehens
regard
tb
follow
world
war
ii
led
multipl
health
organ
advoc
bcg
vaccin
efficaci
proven
earlier
studi
becam
evid
vari
effect
differ
area
world
consequ
introduc
seed
lot
system
lav
uniform
countri
report
ten
bcg
strain
current
use
recent
year
immunogen
bcg
lav
studi
greater
extent
appear
vari
base
age
time
vaccin
locat
previou
exposur
mycobacteria
infect
statist
analys
efficaci
studi
show
bcg
vaccin
effect
provid
protect
sever
extrapulmonari
nonlung
form
pediatr
tb
unreli
protect
adult
pulmonari
tb
howev
despit
variabl
efficaci
bcg
vaccin
incred
benefici
prevent
estim
million
death
hivneg
individu
million
hivposit
individu
alon
tb
remain
one
top
ten
caus
death
world
sourc
major
epidem
develop
countri
addit
hivposit
contraind
bcg
vaccin
although
individu
exponenti
like
develop
activ
tb
anoth
threat
erad
tb
increas
preval
multidrugresist
tuberculosi
mdrtb
extens
drugresist
tb
xdrtb
effort
continu
reach
mileston
establish
end
tb
strategi
current
trajectori
tb
declin
meet
previou
deadlin
although
bcg
lav
play
essenti
role
erad
tb
new
effect
vaccin
strategi
urgent
need
calmett
use
serial
passag
develop
lav
open
new
door
vaccin
product
major
lav
sinc
made
use
method
includ
vaccin
yellow
fever
poliomyel
measl
mump
rubella
typhoid
varicella
zoster
influenza
rotateq
pentaval
reassort
rotaviru
vaccin
made
strategi
like
bcg
vaccin
compris
combin
attenu
human
bovin
strain
viru
techniqu
use
serial
passag
evolv
time
occur
varieti
media
host
organ
effect
lav
diseas
prevent
profound
max
theiler
award
nobel
prize
creation
yellow
fever
lav
remain
recipi
award
develop
vaccin
summar
histori
wellknown
lav
categori
includ
yellow
fever
measl
polio
influenza
vaccin
yellow
fever
yf
seriou
hemorrhag
fever
endem
tropic
subtrop
region
africa
south
america
recogn
one
devast
infecti
diseas
centuri
capabl
kill
thousand
time
yf
caus
yellow
fever
viru
yfv
positivesens
rna
flaviviru
transmit
aed
haemogogu
sabeth
mosquito
speci
first
isol
yfv
obtain
serial
passag
serum
infect
individu
francoi
mayali
asibi
rhesu
macaqu
isol
mayali
use
pasteur
institut
develop
french
neurotrop
vaccin
strain
fnv
discontinu
due
number
encephalit
reaction
vaccin
yfvasibi
strain
isol
passag
max
theiler
rockefel
institut
success
attenu
passag
mous
embryon
tissu
minc
wholechick
embryo
minc
chick
embryo
brain
spinal
cord
remov
lav
caus
mild
diseas
macaqu
human
cohort
confer
protect
immun
yfv
strain
known
basi
yfv
vaccin
use
today
mass
vaccin
campaign
africa
south
america
succeed
control
yellow
fever
endem
area
past
year
howev
recurr
outbreak
episod
taken
place
area
limit
vaccin
coverag
sinc
introduct
dramat
consequ
time
ethiopia
case
fatal
report
deriv
lav
renown
safeti
potenc
immunogen
properti
vaccin
provid
effect
immun
vaccine
day
vaccin
vaccine
within
day
vaccin
incid
seriou
advers
event
vaccineassoci
neurotrop
diseas
yeland
vaccineassoci
viscerotrop
diseas
yelavd
remain
extrem
low
appear
truli
product
stochast
gener
attempt
recreat
futil
diminish
suppli
lav
face
unusu
yf
outbreak
current
caus
concern
sinc
case
yf
nonendem
area
area
less
preval
yf
increas
reason
spread
yfv
area
unknown
could
result
increas
human
activ
ecosystem
sylvat
cycl
yfv
transmiss
occur
due
widen
rang
favor
habitat
yfvcarri
mosquito
travel
due
climat
chang
antivir
treatment
exist
yf
exist
reservoir
diseas
nonhuman
primat
critic
vaccin
area
experienc
yf
outbreak
remain
consist
howev
shortag
vaccin
led
use
faction
dose
vaccin
dose
rang
origin
dose
induc
neutral
antibodi
remain
detect
one
eight
year
post
vaccin
unclear
howev
whether
longterm
immun
lesser
dose
provid
compar
full
lav
dose
global
scale
yf
reemerg
nonendem
area
effect
surveil
protocol
adequ
vaccin
stockpil
key
prevent
futur
outbreak
measl
highli
contagi
ill
produc
negativesens
rna
measl
viru
mv
famili
paramyxovirida
transmit
respir
aerosol
prior
licensur
vaccin
measl
epidem
occur
everi
two
three
year
caus
million
death
annual
mv
first
isol
tissu
cultur
ender
peebl
use
sampl
infect
child
name
david
edmonston
viru
propag
primari
human
kidney
amnion
cell
attenu
passag
chick
embryo
chick
embryo
fibroblast
process
gave
rise
edmonston
b
strain
edmonston
reactogen
vaccin
use
edmonston
b
licens
lav
attenu
five
addit
passag
chick
embryo
fibroblast
c
reactogen
measl
lav
mvlav
led
creation
attenu
strain
aikc
origin
edmonston
strain
schwarz
edmonston
edmonston
zagreb
moraten
edmonston
b
strain
approach
develop
strain
involv
passag
chick
cell
cultur
passag
chick
cell
cultur
elev
lower
temperatur
passag
human
diploid
fibroblast
independ
measl
strain
cam
leningrad
changchun
shanghai
also
produc
mvlav
caus
fever
rash
extent
side
effect
mild
shortliv
safe
effect
afford
mvlav
profound
effect
diseas
incid
measl
decreas
death
due
measl
fell
although
potent
cost
effect
reliabl
mvlav
avail
gap
vaccin
coverag
led
resurg
mani
area
world
death
measl
record
incid
measl
continu
rise
high
communic
mv
necessit
high
level
global
vaccin
coverag
recent
pattern
outbreak
due
vaccin
hesit
potenti
undo
decad
work
invest
control
infecti
diseas
global
vaccin
action
plan
aim
erad
measl
rubella
five
region
mvlav
must
extens
util
accomplish
erad
time
manner
polioviru
lav
brought
oncefear
paralyt
diseas
poliomyel
brink
erad
poliomyel
becam
preval
turn
centuri
instig
epidemiolog
studi
help
character
viru
pathogenesi
pathogen
theori
polioviru
disrupt
pure
neurolog
view
due
motor
neuron
infect
result
diseas
poliomyel
disprov
sabin
scientist
complet
immun
polioviru
requir
vaccin
lav
deriv
three
serotyp
lav
use
polioviru
deriv
sabin
type
vaccin
strain
develop
origin
parent
strain
mahoney
leon
respect
attenu
strain
achiev
tissu
cultur
passag
varieti
cell
type
well
intracerebr
passag
case
follow
serial
passag
serotyp
sabin
select
success
deriv
mahoney
leon
neurovirul
test
monkey
live
oral
polio
vaccin
opv
licens
introduct
opv
decreas
incid
polio
improv
upon
reduct
achiev
inactiv
polio
vaccin
ipv
develop
salk
immedi
use
mass
vaccin
campaign
opv
play
critic
role
global
polio
erad
initi
began
decreas
global
burden
wildtyp
polio
annual
case
case
wildtyp
polioviru
last
seen
declar
erad
wildtyp
polioviru
declar
erad
octob
despit
success
case
polio
pose
global
health
risk
rare
occas
opv
revert
neurovirul
phenotyp
induc
vaccineassoci
paralyt
poliomyel
viru
excret
follow
vaccin
lead
circul
vaccinederiv
poliovirus
cvdpv
cvdpv
control
consist
vaccin
longterm
viru
excret
hypogammaglobulinem
vaccine
known
immunodefici
vaccinederiv
poliovirus
ivdpv
difficult
manag
partner
introduc
polio
endgam
strategi
aim
wildtyp
vaccinederiv
polio
erad
use
bival
opv
ipv
influenza
commonli
flu
highli
contagi
acut
respiratori
infect
caus
singlestrand
rna
segment
influenza
virus
orthomyxoviru
famili
classifi
four
genera
known
influenza
b
c
virus
well
subtyp
base
hemagglutinin
ha
neuraminidas
na
surfac
protein
influenza
affect
adult
children
annual
across
globe
predispos
individu
secondari
infect
pneumonia
vaccin
shown
reduc
influenza
mortal
morbid
complic
antigen
drift
introduct
mutat
gene
segment
antigen
shift
emerg
new
influenza
viru
subtyp
reassort
current
subtyp
inactiv
vaccin
lav
current
use
influenza
viru
trival
inactiv
vaccin
tiv
either
wholeviru
split
viru
viru
disrupt
deterg
subunit
vaccin
contain
strainspecif
ha
na
antigen
contrast
liveattenu
influenza
vaccin
laiv
coldadapt
reassort
vaccin
made
gene
encod
ha
na
protein
recent
season
wildtyp
strain
six
addit
gene
segment
attenu
donor
strain
influenza
viru
isol
nasal
discharg
infect
patient
wilson
smith
sir
christoph
andrew
sir
patrick
laidlaw
isol
procedur
use
develop
inactiv
influenza
vaccin
grown
chorioallantoid
membran
embryon
egg
cell
cultur
purifi
centrifug
chemic
inactiv
split
viru
subunit
inactiv
vaccin
follow
develop
wholeviru
inactiv
influenza
vaccin
vaccin
use
wholeviru
influenza
vaccin
due
reduc
reactogen
laiv
progress
monoval
trival
quadrival
new
genera
influenza
viru
discov
success
stabl
laiv
reassort
coldadapt
vaccin
passag
progress
lower
temperatur
c
reach
primari
chicken
kidney
cell
embryon
egg
reduc
growth
laiv
higher
temperatur
restrict
viru
replic
primarili
upper
respiratori
tract
mimic
natur
infect
prevent
viral
spread
lower
respiratori
tract
throughout
bodi
laiv
use
russia
decad
advers
effect
transient
febril
reaction
first
laiv
use
unit
state
trival
coldadapt
vaccin
licens
although
tiv
frequent
use
season
influenza
vaccin
immun
subunit
tiv
reli
ha
na
protein
specif
influenza
strain
contrast
inclus
six
viral
protein
coldadapt
donor
influenza
strain
enabl
laiv
exhibit
heterosubtyp
protect
improv
viral
clearanc
differ
substrain
influenza
one
vaccin
howev
contraind
due
age
asthma
immunosuppress
pregnanc
often
preclud
use
laiv
comparison
tiv
improv
understand
laiv
attenu
would
assist
develop
new
influenza
vaccin
provid
longerlast
immun
protect
multipl
strain
influenza
high
potenc
lav
well
establish
howev
attenu
immunogen
origin
pure
empir
process
rather
ration
engin
develop
whether
lav
isol
relat
pathogen
propag
variou
way
attenu
serial
passag
environ
pathogen
grown
influenc
evolutionari
path
therefor
alter
aspect
infecti
cycl
reason
origin
vaccinia
basi
smallpox
lav
lost
histori
prior
erad
smallpox
attempt
recreat
vaccinialik
lav
passag
variola
viru
major
minor
embryon
egg
tissu
cultur
mice
unsuccess
addit
even
method
lav
passag
describ
detail
case
recreat
vaccin
alway
possibl
futur
lav
gener
therefor
empir
must
stem
welldevelop
understand
differenti
hostpathogen
interact
lav
virul
pathogen
display
direct
genet
comparison
lav
strain
virul
counterpart
use
hypothes
correl
attenu
immunogen
exampl
case
vaccinederiv
paralyt
poliomyel
vapp
increas
neurovirul
associ
mutat
noncod
region
three
opv
strain
passag
human
gastrointestin
tract
interestingli
besid
vaccinia
virusderiv
smallpox
lav
deliber
reassort
laiv
lav
tend
show
high
genet
similar
pathogen
deriv
yfvasibi
diverg
nucleotid
genom
amino
acid
chang
scatter
throughout
genom
addit
edmonstonderiv
mvlav
shown
differ
edmonston
strain
kb
delet
seen
bcg
lav
account
littl
bp
genom
bovi
genet
variat
lav
strain
howev
complic
extrapol
data
addit
kb
delet
attenu
bcg
lav
strain
addit
delet
name
kb
andor
kb
descript
genet
differ
alon
hardli
explain
effect
hostpathogen
interact
immun
regul
therefor
larg
bodi
research
molecular
mechan
govern
lav
attenu
conduct
vitro
lav
instanc
found
differ
cell
entri
mechan
comparison
virul
counterpart
enhanc
receptor
util
mvlav
describ
influenc
mutat
hemagglutinin
h
protein
yfvasibi
also
exhibit
distinct
usag
cell
entri
pathway
cell
surfac
molecul
associ
differenti
viral
spread
cellintrinsicimmunerespons
induct
differ
viral
replic
cytokin
induct
also
observ
cell
cultur
replic
extens
yfvasibi
hepatoma
cell
line
howev
yfvasibi
caus
stronger
sustain
proinflammatori
respons
primari
human
vascular
endotheli
cell
kupffer
cell
mdm
monocytederiv
dendrit
cell
modc
sabin
type
opv
display
genet
differ
polioviru
type
decreas
bind
polypyrimidin
tractbind
protein
ptb
viral
intern
ribosom
entri
site
ire
lower
ptb
bind
sabin
type
opv
ire
impair
protein
translat
neuron
suggest
mediat
viral
attenu
central
nervou
system
final
reduc
replic
dendrit
cell
dc
vitro
suggest
promot
antigen
present
lymph
node
ln
prevent
dc
apoptosi
unlik
yfvasibi
replic
modc
also
stimul
product
cell
anoth
interest
concept
explain
lav
attenu
reli
upon
genet
stabil
pathogen
instanc
poorli
prone
diversifi
multipl
quasispeci
comparison
yfvasibi
yfvasibi
diversif
associ
emerg
attenu
mutat
recent
studi
report
stronger
resist
mutat
suggest
yfv
attenu
could
relat
higher
fidel
replic
complex
although
vitro
model
use
understand
lav
model
hostlav
interact
spatiotempor
manner
relev
tissu
context
remain
fundament
accur
investig
molecular
mechan
govern
lav
attenu
immunogen
end
anim
model
use
conduct
research
vivo
instanc
delet
bcg
lav
report
prevent
cytolysi
produc
earli
secretori
antigen
target
decreas
tissu
invas
mous
model
mice
defect
type
interferon
signal
employ
explor
mechan
attenu
immunogen
humor
cell
respons
cell
respons
found
critic
yfvinduc
protect
respons
also
report
restrict
dissemin
yfvasibi
mice
beyond
mice
nhp
also
serv
investig
impact
cellcultur
adapt
mutat
viral
virul
inflammatori
respons
passag
pathogen
wildtyp
mv
vero
cell
chicken
embryo
fibroblast
led
emerg
sever
adapt
mutat
result
attenu
clinic
symptom
rhesu
macaqu
interestingli
backtoback
comparison
earli
transcriptom
respons
asibi
infect
conduct
rhesu
macaqu
number
differenti
express
gene
peripher
mononuclear
cell
higher
upon
yfvasibi
infect
express
chang
mostli
connect
dysregul
immun
respons
apoptosi
contrast
gene
express
chang
infect
mainli
link
innat
immun
although
agreement
found
vivo
vitro
studi
discrep
also
arisen
sabin
type
opv
attenu
vitro
upon
exposur
high
temperatur
c
unlik
parent
strain
mahoney
howev
genet
determin
temperatur
sensit
contribut
viral
attenu
transgen
mous
model
addit
nycbhderiv
lav
strain
examin
lee
et
al
replic
wildtyp
level
vitro
replic
mous
epithelium
differ
greatli
wildtyp
vaccinia
viru
immunogen
effect
dosedepend
categori
discrep
also
report
instanc
rout
administr
seem
affect
viru
protein
role
vaccinia
viru
infect
bcginduc
immun
respons
nhp
moreov
multipl
studi
found
greater
ifn
product
mvlav
strain
potenti
presenc
copyback
defect
interf
di
rna
laboratori
viru
stock
increas
interferon
ifn
interferonstimul
gene
isg
level
among
multipl
effect
may
confound
previou
result
dispar
vivo
model
also
observ
mice
defect
type
interferon
signal
suggest
relev
system
investig
protect
immun
howev
import
number
gene
upstream
downstream
type
interferon
signal
pathway
upregul
upon
vaccin
human
furthermor
although
author
report
mous
cell
contribut
protect
mice
defect
type
interferon
signal
multipl
studi
describ
critic
mobil
human
cell
toward
robust
effector
memori
phenotyp
vaccin
human
vaccine
final
discrep
also
observ
cytokin
respons
human
rhesu
macaqu
modc
upon
infect
lav
attenu
multifacet
complex
topic
histori
lav
passag
vari
mosaic
efficaci
product
left
near
imposs
trace
root
understand
lav
attenu
appear
mainli
restrict
either
genet
chang
upstream
vaccin
process
immun
correl
downstream
vaccin
antibodi
product
howev
immunolog
mechan
hostpathogen
interact
govern
attenu
vaccin
remain
unchart
explor
mechan
choic
right
experiment
system
critic
import
exemplifi
instanc
disagr
describ
accur
understand
lavinduc
immun
therefor
fulli
reliant
suitabl
vivo
model
abl
recapitul
human
immun
lav
comprehens
although
exhaust
summari
lav
attenu
mechan
provid
tabl
associ
follow
addit
refer
mous
nhp
pig
histor
aspect
liveattenu
vaccin
lav
creation
method
gener
well
date
pathogen
isol
attenu
list
mechan
lav
attenu
categor
genet
similar
parent
strain
virul
strain
except
smallpox
influenza
lav
ii
studi
mechan
govern
lav
attenu
perform
vitro
iii
anim
model
use
vivo
investig
nhp
nonhuman
primat
na
nonapplic
refer
link
associ
literatur
indic
bracket
limit
understand
mechan
lav
attenu
immunogen
mostli
origin
lack
vivo
system
suitabl
investig
antilav
immun
although
vitro
studi
shed
light
characterist
lav
see
section
lav
attenu
immunogen
defin
specif
interact
differ
tissu
complex
cell
popul
time
space
interplay
remain
imposs
model
cell
cultur
dish
mous
model
truli
transform
understand
human
immunolog
like
continu
although
serv
model
organ
investig
antilav
immun
evalu
lav
candid
vivo
import
limit
concern
stall
use
purpos
despit
share
mani
physiolog
metabol
process
mous
man
diverg
evolutionarili
million
year
ago
evolutionari
diverg
differenti
shape
architectur
immun
system
speci
therefor
lead
import
differ
organ
mobil
immun
system
fight
given
diseas
numer
immunolog
differ
mice
human
differ
immun
cell
composit
blood
differ
spatiotempor
express
mani
immun
protein
receptor
pattern
recognit
receptor
cluster
differenti
immunoglobulin
fc
receptor
major
histocompat
complex
mhc
etc
differ
hematopoiesi
differ
cytokin
function
aim
investig
antilav
immun
highest
possibl
resolut
translat
immunolog
mechan
mice
human
becom
peril
moreov
mani
viral
bacteri
pathogen
display
narrow
host
tropism
often
restrict
human
specif
primat
speci
exampl
natur
resist
mice
viral
pathogen
mv
yfv
dengu
viru
ebola
viru
zika
viru
add
addit
layer
limit
convent
mous
model
nhp
use
resourc
studi
antilav
immun
well
evalu
novel
lav
candid
especi
macaqu
intens
use
evalu
immunogen
lav
strategi
target
human
immunodefici
viru
howev
sever
humantrop
virusesi
viru
replic
poorli
nhp
speci
therefor
mani
lav
strategi
evalu
nhp
use
liveattenu
simian
immunodefici
viru
siv
simian
version
replic
nhp
speci
addit
strategi
employ
relat
virus
engin
virus
harbor
siv
antigen
also
test
nhp
nhp
also
employ
investig
andor
evalu
immunogen
mani
lav
viral
vector
harbor
ebola
viru
glycoprotein
laiv
opv
mvlav
bcg
liveattenu
venezuelan
equin
enceph
viru
liveattenu
zika
viru
nhp
model
lav
research
howev
present
signific
limit
first
pathogen
strictli
restrict
human
tropism
impos
use
surrog
pathogen
andor
host
environ
natur
permiss
human
pathogen
target
second
nhp
studi
costli
requir
complic
logist
adequ
reagent
limit
avail
final
whether
nhp
cellintrins
innat
immun
respons
differ
human
antigen
stimul
unclear
may
depend
experiment
context
therefor
although
certain
nhp
repres
invalu
system
lav
investig
develop
need
complement
costeffect
access
model
allow
monitor
humanspecif
immun
respons
humanpathogenspecif
interact
major
insight
antilav
immun
obtain
cohort
human
vaccine
instanc
studi
identifi
specif
cellular
transcriptom
epigenet
signatur
defin
lav
immunogen
blood
human
vaccine
provid
uniqu
insight
immun
respons
mobil
upon
lav
vaccin
human
howev
studi
fall
short
probe
fundament
mechan
govern
lav
attenu
immunogen
sever
reason
first
human
cohort
studi
often
restrict
analysi
peripher
immun
respons
upstream
immunolog
event
occur
site
vaccin
drain
lymph
node
critic
pathogenshost
interact
prime
immun
system
toward
specif
direct
remain
inaccess
human
vaccine
second
captur
key
immunolog
mechan
regul
defin
immunogen
requir
perform
backtoback
comparison
immun
respons
induc
given
lav
virul
strain
deriv
relat
howev
obviou
ethic
reason
possibl
cohort
human
patient
final
studi
provid
evid
age
immunolog
histori
microbiota
statu
influenc
immun
respons
pathogen
vaccin
therefor
identifi
immunolog
regul
defin
specif
immun
respons
lav
independ
interindividu
variat
may
impact
respons
remain
complex
task
altogeth
limit
mous
nhp
human
model
highlight
need
altern
vivo
system
would
success
combin
advantag
model
lessen
limit
mice
engraft
human
tissu
especi
compon
human
immun
system
nice
fit
definit
per
definit
human
mice
refer
mice
engraft
human
tissu
andor
express
human
gene
focu
mice
engraft
compon
human
immun
system
mice
describ
past
current
model
relev
studi
lavinduc
immun
stori
mice
began
develop
immunodefici
mous
strain
mous
harbor
sever
combin
immunodefici
scid
mutat
mutat
prkdc
gene
report
lack
function
b
cell
defect
v
j
recombin
mice
defect
express
two
recombin
activ
gene
also
report
display
function
b
cell
similar
mechan
late
transplant
adult
scid
mice
fetal
human
hematopoiet
stem
cell
hsc
tissu
peripher
blood
leukocyt
led
differenti
human
b
cell
vivo
human
hsc
engraft
bgmuxid
mice
also
report
period
anim
athym
lower
level
natur
killer
nk
cell
lymphokineactiv
killer
cell
lak
intraven
inocul
human
bonemarrowderiv
cell
adult
irradi
bgmuxid
mice
led
prolifer
differenti
hsc
macrophag
progenitor
vivo
engraft
anim
led
higher
number
progenitor
scid
mice
like
due
absenc
nk
lak
activ
bgmuxid
mice
year
later
adult
irradi
scid
mice
transplant
human
bone
marrow
cell
treat
multipl
human
cytokin
name
erythropoietin
human
mast
cell
growth
factor
fusion
protein
human
human
granulocytemacrophag
coloni
stimul
factor
could
repopul
differenti
human
cell
deriv
sever
myeloid
lymphoid
lineag
bone
marrow
howev
engraft
level
still
remain
low
scid
mice
built
within
nonobes
diabet
nod
background
identifi
support
higher
level
hsc
engraft
comparison
previous
test
genet
background
around
ten
year
later
underli
mechan
superior
engraft
found
relat
polymorph
sirpa
allel
nod
cell
surfac
receptor
express
surfac
macrophag
encod
sirpa
allel
display
signific
similar
human
one
comparison
express
mice
genet
background
similar
allow
nod
mous
macrophag
bind
human
therefor
recogn
human
hematopoiet
cell
self
anoth
import
step
develop
permiss
mous
genet
background
human
hsc
engraft
went
develop
mous
defect
carri
mutat
common
gamma
chain
interleukin
il
receptor
receptor
multipl
cytokin
disrupt
signal
induc
sever
defici
nk
cell
develop
matur
lead
sever
immunodefici
permiss
environ
human
hsc
engraft
adult
supplement
unsuppl
exogen
administr
human
cytokin
adult
nodscid
mice
anoth
import
step
follow
demonstr
intrahepat
inject
human
cell
newborn
null
nodscid
null
mice
led
induct
low
albeit
signific
function
adapt
respons
mice
open
door
novel
investig
human
immun
vivo
altern
model
nodscid
null
mice
name
nodscid
jak
null
also
report
model
jak
gene
encod
tyrosin
kinas
critic
signal
knockedout
instead
result
complet
lack
b
nk
cell
vast
major
mous
strain
use
human
hsc
engraft
still
much
reli
upon
mutat
polymorph
describ
commonli
use
strain
nodscid
null
nsg
nog
harbor
nodltsz
nodshi
background
respect
null
brg
null
nrg
figur
summar
develop
timelin
model
despit
signific
improv
hsc
engraft
develop
mice
nsg
nog
brg
nrg
background
abl
mount
potent
innat
antigenspecif
human
immun
respons
remain
consider
challeng
inde
strain
bear
import
limit
restrict
develop
function
human
immun
system
lack
proper
human
cytokin
environ
ii
absenc
larg
nich
space
iii
limit
myelopoiesi
iv
lack
special
human
microenviron
v
lack
human
mhc
therefor
consider
effort
undertaken
last
decad
gener
novel
xenorecipi
strain
overcom
multipl
limit
develop
timelin
model
describ
shown
figur
cytokin
environ
nich
space
one
approach
enhanc
mice
notabl
consist
gener
xenorecipi
strain
express
human
cytokin
larg
number
mous
cytokin
crossreact
human
receptor
absenc
cytokinemedi
signal
hypothes
affect
mani
arm
immun
system
mice
myeloid
nk
cell
develop
cell
educ
b
cell
matur
consist
mani
group
report
develop
brg
transgen
express
human
sirpa
nsg
nog
mice
express
one
sever
human
cytokin
transgen
knockin
approach
human
thrombopoietin
tpo
granulocytemacrophag
colonystimul
factor
gmcsf
stem
cell
factor
scf
andor
macrophag
coloni
stimul
factor
mcsf
model
show
enhanc
human
hematopoiesi
well
superior
develop
differenti
multipl
myeloid
cell
subset
one
model
name
mistrg
hh
hh
sirpa
tg
tpo
hh
combin
knockin
human
thrombopoietin
gmcsf
mcsf
display
enhanc
innat
immun
viral
bacteri
infect
comparison
nsg
mice
altern
approach
promot
enhanc
human
hematopoiesi
myeloid
cell
develop
involv
increas
stem
cell
nich
space
human
hematopoiet
lineag
develop
nsg
nog
nrg
brg
mice
murin
myelopoiesi
restrict
therefor
closingup
nich
space
requir
proper
human
myelopoiesi
addit
presenc
semi
function
mous
myeloid
compart
also
interfer
initi
humanlik
innat
respons
mice
henc
introduc
bia
human
immun
respons
analysi
initi
strategi
enhanc
nich
space
human
mice
consist
irradi
newborn
adult
immunodefici
mice
prior
engraft
howev
approach
neg
longterm
effect
anim
health
recent
nsg
brg
mice
harbor
mutat
gene
code
respect
nsgkit
nbsgw
brgkit
wvwv
brgwv
gener
ckit
receptor
express
high
level
cell
surfac
hsc
progenitor
cell
ckitmedi
signal
shown
regul
hematopoiesi
interestingli
adult
nonirradi
nsbgw
brgwv
mice
demonstr
robust
sustain
engraft
human
hsc
similar
level
irradi
nsg
mice
follow
inject
cord
bloodderiv
human
cell
underscor
human
stem
cell
nich
space
significantli
open
without
need
irradi
fm
like
tyrosin
kinas
fetal
liver
cell
surfac
receptor
broadli
express
earli
hematopoiet
precursor
bone
marrow
myelopoiesi
impair
mice
inject
human
version
ligand
shown
promot
dendrit
cell
develop
nodscid
mice
howev
crossreact
mous
allow
dual
expans
mous
human
myeloid
compart
convent
immunodefici
strain
recent
nrg
brg
brghsirpa
mice
nrgf
brgf
brgsf
respect
expressingor
inject
report
promot
select
expans
human
dendrit
cell
natur
killer
cell
follow
human
hsc
engraft
strong
myeloid
develop
mice
like
result
effect
synergi
increas
myeloid
nich
space
caus
defici
robust
signal
human
cell
final
worth
note
express
human
cytokin
knockin
approach
mice
also
repres
great
strategi
open
nich
space
inde
approach
concurr
promot
develop
matur
human
hematopoiet
lineag
deplet
mous
hematopoiet
compart
essenti
cytokin
requir
proper
develop
function
band
tcell
primarili
educ
bone
marrow
thymu
respect
primari
lymphoid
tissu
undergo
sever
round
posit
andor
neg
select
process
fundament
proper
lymphocyt
matur
antigen
reactiv
specif
regul
extens
crosstalk
immatur
lymphocyt
larg
varieti
cell
type
molecul
member
mhc
resid
primari
lymphoid
tissu
initi
approach
gener
mice
express
transgen
mhc
molecul
educ
human
cell
mous
thymu
track
human
antigenspecif
cell
upon
microbi
challeng
howev
elabor
strategi
involv
construct
mice
engraft
human
primari
lymphoid
tissu
order
physiolog
model
human
hematopoiesi
lymphocyt
educ
introductori
studi
report
coengraft
small
fragment
fetal
liver
thymu
adult
scid
mice
also
refer
scidhu
model
led
longterm
mainten
sever
human
hematopoiet
progenitor
sustain
human
lymphopoiesi
year
later
mice
coengraft
human
hsc
small
piec
fetal
liver
thymu
name
bone
marrowliverthymu
mice
blt
mice
gener
use
nodscid
background
later
nsg
background
studi
blthi
mice
shown
display
enhanc
lymphopoiesi
tcell
select
human
mhc
molecul
blthi
mice
notabl
constitut
model
choic
investig
infecti
cycl
vivo
mucos
infect
persist
viremia
cellular
responsesalbeit
limitedcould
recapitul
model
blthi
mice
also
use
system
investig
replic
dynam
dengu
viru
denv
vivo
well
antidenv
adapt
immun
howev
major
limit
blt
model
absolut
relianc
fetal
tissu
therefor
altern
approach
involv
engraft
immunodefici
mous
strain
embryon
stem
cellderiv
thymic
epitheli
progenitor
neonat
thymu
recent
propos
bone
marrow
critic
surviv
mainten
hsc
well
bcell
educ
matur
sever
group
report
develop
mous
model
use
mainli
nsg
nsgderiv
strain
engraft
bone
marrowderiv
mesenchym
stromal
cell
predifferenti
lead
format
human
ossicl
vivo
studi
subsequ
inject
hsc
ossicl
intraven
result
develop
human
microenviron
abl
recapitul
human
bone
marrow
morpholog
function
vivo
well
physiolog
relev
human
hematopoiesi
anoth
major
caveat
immunodefici
mous
strain
lack
function
drain
lymph
node
ln
null
immunodefici
mice
defect
signal
result
absenc
lymphoid
tissu
induc
cell
lti
develop
interestingli
thymic
stromal
lymphopoietin
tslp
share
structur
function
homolog
signal
receptor
independ
recent
shown
tslp
overexpress
compens
lack
signal
promot
robust
ln
develop
brghsirpa
mice
brgst
even
though
secondari
lymphoid
structur
complet
consid
human
microenviron
per
se
mous
ln
effect
repopul
human
hematopoiet
cell
brg
mice
provid
suitabl
nich
human
tand
bcell
prime
immun
lead
enhanc
human
antigenspecif
respons
altern
approach
restor
mous
ln
also
report
nog
mice
harbor
transgen
code
murin
control
endogen
promot
gener
allow
select
reexpress
specif
lti
lineag
brgst
mice
model
abl
mount
enhanc
antigenspecif
igg
respons
beyond
genet
background
modif
given
mous
multipl
protocol
engraft
describ
significantli
impact
human
immun
reconstitut
engraft
protocol
compos
sever
variabl
mainli
includ
sourc
hsc
engraft
fetal
tissu
mous
age
transplant
rout
sex
condit
although
engraft
protocol
wide
use
across
sever
strain
mice
interrog
mani
biolog
process
protocol
instanc
includ
engraft
addit
human
tissu
matric
specif
certain
strain
biolog
question
therefor
addit
mous
strain
use
import
understand
characterist
engraft
protocol
employ
make
sure
appropri
given
investig
human
hsc
isol
fetal
liver
adult
donor
latter
includ
variou
sourc
cord
blood
adultmobil
peripher
blood
adult
bone
marrow
hsc
either
inject
newborn
mice
day
old
intraven
intrafemor
intrahepat
intracardiac
rout
adult
mice
week
age
intraven
intrafemor
intrasplen
intraperiton
rout
human
peripher
blood
lymphocyt
also
directli
inject
adult
mice
intrasplen
intraven
intraperiton
rout
interestingli
sex
also
report
engraft
variabl
specif
experiment
set
number
inject
cell
vari
cell
per
mice
depend
model
use
given
limit
avail
hsc
common
singl
donor
use
gener
sever
cohort
mice
although
like
allow
experi
overcom
interindividu
variat
gener
robust
dataset
lack
donor
divers
also
repres
limit
overr
signific
biolog
aspect
investig
model
openup
nich
space
decreas
graft
reject
newborn
adult
mice
precondit
prior
engraft
subleth
irradi
antibodypretreat
howev
mous
model
capabl
reach
high
level
human
immun
reconstitut
without
need
precondit
recent
describ
human
immun
reconstitut
take
averag
week
follow
engraft
lifespan
mice
rang
wide
six
month
month
depend
protocol
genet
background
model
employ
inde
sever
mous
model
prone
graftversushost
diseas
due
prime
allogen
cell
respons
murin
myeloid
cell
anemia
due
instanc
human
macrophag
activ
murin
red
blood
cell
mention
section
human
microenviron
lymphocyt
educ
engraft
protocol
also
includ
engraft
addit
human
tissu
matric
includ
fetal
neonat
thymu
fetal
liver
bonemarrowderiv
mesenchym
stromal
cell
among
cellstissu
thymu
liver
tissu
commonli
engraft
kidney
capsul
prior
inject
autolog
hsc
intraven
rout
develop
human
ossicl
bonemarrowderiv
mesenchym
stromal
cell
engraft
subcutan
either
direct
inject
surgic
implant
autolog
hsc
subsequ
inject
intraven
intraossicl
rout
mice
potenti
truli
transform
understand
lav
provid
uniqu
opportun
investig
molecular
basi
govern
high
immunogen
current
establish
lav
therefor
shed
new
light
onto
understand
human
immun
vaccin
design
addit
also
present
costeffect
way
evalu
replic
fit
immunogen
attenu
safeti
lav
candid
human
immunolog
context
review
convent
emerg
model
mice
har
investig
lav
replic
fit
safeti
immunogen
summari
contribut
mice
lav
research
also
found
figur
mice
intens
use
investig
infecti
cycl
vivo
immun
respons
howev
limit
studi
employ
system
evalu
efficaci
safeti
attenu
strategi
one
studi
report
strain
hivrta
tattar
mechan
requir
viru
replic
transcript
inactiv
viral
protein
nef
replac
doxycyclinedepend
transcript
system
author
show
hivrta
could
lead
product
infect
doxycyclinef
brghi
mice
without
cell
deplet
importantli
viru
found
escap
doxycyclin
control
time
revert
toward
wild
type
tattar
mechan
year
later
second
version
viru
express
ubiquitinprocess
rtaubnef
cassett
hivrtaubnef
found
replic
effect
nsghi
mice
hivrta
without
impact
cell
count
altogeth
studi
demonstr
mice
repres
use
system
evalu
replic
kinet
safeti
liveattenu
lymphotrop
virus
narrow
tropism
human
nodscid
jak
null
noj
mice
shown
suscept
mvlav
infect
especi
evid
studi
mvlav
could
significantli
detect
blood
spleen
bone
marrow
human
noj
nonhuman
noj
mice
suscept
mvlav
use
evalu
vaccin
revers
stabil
time
specif
mice
employ
investig
whether
longterm
passag
avirul
measl
vaccin
strain
moraten
strain
could
caus
enhanc
virul
thymic
tissu
adapt
time
interestingli
moraten
strain
collect
day
post
vaccin
thymu
mice
show
high
virul
thymu
implant
comparison
origin
moraten
strain
work
demonstr
mice
repres
valuabl
resourc
evalu
vaccin
safeti
recent
report
nrg
mice
engraft
human
hsc
nrghi
suscept
inde
although
nrg
mice
engraft
murin
hsc
nrgmi
permiss
infect
reconstitut
nrg
mice
human
hematopoiet
cell
led
persist
infect
peripher
blood
spleen
demonstr
preferenti
tropism
human
cell
track
viral
rna
multipl
subset
human
immun
system
abl
probe
cellular
tropism
time
space
multipl
human
hematopoiet
lineag
use
nrghi
mice
mice
deplet
signal
hematopoiet
compart
also
identifi
speciesspecif
interact
compart
potenti
regul
outcom
infect
altogeth
work
provid
import
evid
mice
serv
uniqu
system
defin
dynam
interact
lav
compon
human
immun
system
time
space
liveattenu
influenza
vaccin
laiv
like
repres
lav
investig
use
mice
yu
et
al
report
use
nsghi
mous
model
engraft
hlaa
hsc
treat
reinject
autolog
cell
prior
vaccin
trival
influenza
lav
follow
vaccin
cell
target
hlaa
epitop
influenza
matrix
protein
nonstructur
protein
found
expand
blood
spleen
lung
underscor
success
adapt
immun
prime
model
importantli
prime
report
myeloiddepend
highlight
critic
need
myeloid
compart
mice
model
antilav
immun
followup
studi
author
identifi
dendrit
cell
induc
differenti
accumul
mucos
effector
cell
manner
lung
follow
laiv
vaccin
final
third
public
identifi
dendrit
cell
major
driver
establish
respons
lung
upon
laiv
infect
promot
differenti
cell
ligand
overal
studi
demonstr
mice
success
employ
uncov
immunolog
mechan
regul
cell
prime
differenti
relev
tissu
lav
infect
nsghi
mice
report
mimic
clinic
featur
human
tuberculosi
infect
follow
aerosol
infect
pulmonari
lesion
necrot
granuloma
display
similar
observ
patient
could
observ
author
also
demonstr
relev
infect
model
evalu
drug
regimen
tuberculosi
vivo
anoth
studi
nrghi
mice
immun
subcutan
bcg
vaccin
challeng
four
week
later
tuberculosi
via
respiratori
rout
bcg
abl
partial
protect
nrghi
mice
tuberculosi
infect
demonstr
reduc
bacteri
load
granulomat
lesion
lung
author
therefor
conclud
mice
repres
relev
platform
evalu
novel
vaccin
strategi
tuberculosi
method
implement
test
novel
adenoviralvector
vv
vaccin
express
immunodomin
tuberculosi
antigen
year
addit
studi
differ
group
report
analysi
cell
phenotyp
express
noghi
mice
upon
tuberculosi
infect
well
bcg
vaccin
prior
tuberculosi
infect
author
found
evid
potenti
tcell
activ
upon
tuberculosi
challeng
lung
suggest
bcg
vaccin
affect
distribut
tcell
activ
phenotyp
tissu
upon
subsequ
tuberculosi
infect
howev
unlik
previou
studi
author
find
bcg
could
confer
level
protect
tuberculosi
noghi
mice
contrast
mice
hartley
guinea
pig
partial
protect
observ
altogeth
studi
highlight
mice
potenti
uncov
molecular
basi
bcginduc
immun
howev
also
underscor
need
advanc
mous
model
abl
accur
reproduc
recapitul
human
bcginduc
immun
previou
studi
use
convent
mice
demonstr
import
myeloid
compart
mice
accur
investig
antilav
immun
recent
report
nrgfhi
mice
see
section
cytokin
environ
nich
space
model
descript
nrgfhi
mice
express
transgen
hlaa
new
mous
model
investig
immun
model
adenovirusmedi
express
promot
select
expans
human
dendrit
cell
myeloid
cell
granulocyt
unlik
convent
nrg
nsg
brg
mice
expressioninject
lead
expans
human
murin
myeloid
compart
although
might
issu
lav
mous
interferon
respons
shown
strongli
restrict
infect
mous
model
infect
contrast
human
overcom
respons
therefor
expans
myeloid
compart
convent
mous
strain
lead
import
immun
interfer
mous
human
hematopoiet
compart
unlik
convent
nrghi
mice
human
myeloid
compart
expand
found
mice
mount
peripher
transcriptom
respons
upon
share
key
similar
respons
observ
human
vaccine
mice
consist
abl
mount
cell
respons
well
respons
led
clearanc
viral
rna
peripher
blood
unlik
convent
nrghi
mice
infect
persist
time
peripheri
work
demonstr
strong
potenti
secondgener
mice
emerg
model
uncov
fundament
immunolog
process
regul
adapt
immun
prime
vivo
human
context
therefor
shed
light
elus
mechan
govern
lavinduc
protect
immun
although
mice
instrument
investig
infecti
cycl
import
viral
bacteri
pathogen
use
model
studi
establish
candid
lav
remain
scarc
one
potenti
reason
explain
scarciti
research
current
limit
model
unlik
virul
pathogen
often
display
low
immunogen
featur
evad
imped
immun
respons
lead
clinic
symptom
lav
strongli
immunogen
pathogen
requir
vivo
system
power
enough
effect
read
har
order
develop
strong
longlast
respons
therefor
although
convent
mice
consid
satisfi
enough
studi
specif
immunolog
process
virul
pathogen
infect
investig
lavinduc
immun
requir
model
abl
mount
polyfunct
potent
longlast
respons
involv
multipl
arm
innat
adapt
immun
system
howev
convent
mice
like
nodscid
nrg
nsgnog
brg
display
major
caveat
low
myeloid
engraft
lack
import
lymphoid
tissu
absenc
proper
lymphocyt
educ
therefor
make
model
poorli
suitabl
investig
lavinduc
immun
mice
still
work
progress
like
alway
model
emerg
past
five
year
repres
promis
step
forward
develop
better
mice
lav
research
instanc
model
enhanc
myeloid
nk
engraft
mistrg
report
display
superior
andor
b
cell
activ
upon
microbi
challeng
convent
model
specif
mice
provid
demonstr
enhanc
human
myeloid
nk
compart
could
promot
superior
innat
adapt
immun
respons
lav
mice
nevertheless
major
challeng
need
overcom
establish
model
abl
mount
strong
sustain
b
cell
respons
would
resembl
observ
human
recent
report
new
methodolog
quantit
evalu
qualiti
human
immun
respons
mice
defin
correl
index
peripher
transcriptom
respons
measur
given
mous
human
follow
vaccin
although
abl
show
nrghi
significantli
lower
correl
index
mice
correl
index
latter
model
found
reach
result
highlight
major
refin
still
urgent
need
second
gener
mice
allow
accur
model
human
immun
respons
lav
backtoback
compar
studi
respons
human
mice
critic
help
ration
guid
design
novel
model
evalu
benefit
specif
requir
given
import
myeloid
nk
compart
prime
adapt
immun
respons
one
area
improv
reli
upon
enhanc
human
cytokin
environ
recent
model
combin
knockin
multipl
cytokin
tpo
gmcsf
mcsf
coengraft
novel
cytokineenhanc
mice
human
hsc
human
thymu
andor
ossicl
would
provid
optim
environ
lymphocyt
educ
matur
prime
would
highli
relev
lav
research
model
combin
superior
myeloid
engraft
via
human
cytokin
knockin
mous
mhc
knockout
transgen
express
larg
panel
human
mhc
class
ii
could
also
repres
suitabl
altern
figur
larg
number
lav
well
vaccin
inject
intramuscularli
therefor
prime
immun
respons
drain
ln
howev
current
mice
use
lav
research
lack
function
secondari
lymphoid
structur
defect
signal
see
section
human
microenviron
lymphocyt
educ
suggest
immun
prime
mice
upon
lav
infect
either
extrem
limit
use
intramuscular
rout
occur
irrelev
tissu
context
use
rout
infect
prime
mostli
occur
spleen
use
intraven
rout
infect
sever
strategi
suggest
andor
report
gener
mice
ln
includ
among
cytokinemedi
restor
mous
ln
engraft
exvivo
gener
human
artifici
ln
direct
engraft
human
ln
mice
model
combin
function
ln
structur
primari
lymphoid
human
tissu
human
mhc
class
ii
express
well
enhanc
myeloidnk
compart
could
repres
fantast
resourc
lav
research
figur
model
would
open
major
avenu
new
rang
studi
human
immunolog
mechan
govern
lav
immunogen
attenu
could
decrypt
relev
tissu
cellular
context
way
possibl
human
vaccine
human
tissu
could
enhanc
lavinduc
immun
mice
convent
mous
strain
coengraft
human
liver
human
hsc
previous
report
shown
relev
system
studi
instanc
hepat
b
viru
infect
replic
inducedimmun
respons
liver
known
host
sever
immun
function
product
secret
acut
phase
protein
product
complement
kupffercel
mediat
immun
regul
therefor
like
immun
function
liver
could
synerg
immun
system
coengraft
refin
mous
model
one
describ
figur
recent
blthi
mice
engraft
human
lung
report
author
show
human
lung
tissu
could
repopul
autolog
human
hematopoiet
cell
mice
could
mount
humor
tcell
respons
follow
microbi
challeng
human
lung
tissu
could
relev
investig
immun
respons
lav
administr
respiratori
rout
laiv
instanc
figur
final
evid
point
role
microbiota
regul
immun
respons
vaccin
recent
studi
conduct
human
vaccine
notabl
found
antibiot
treatment
impair
iga
igg
respons
follow
influenza
vaccin
suggest
particular
bacteri
speci
modul
adapt
respons
vaccin
mice
present
signific
advantag
human
studi
microbiota
microbiom
easili
track
manipul
throughout
anim
life
protocol
recent
develop
gener
mice
engraft
human
microbiota
preliminari
studi
conduct
convent
mous
model
approach
role
microbiota
regul
human
health
develop
innov
mous
model
abl
mount
superior
adapt
respons
coengraft
human
microbiota
would
open
notabl
opportun
investig
lavinduc
immun
relev
physiolog
context
better
understand
microbiotamedi
regul
immun
prime
figur
lav
undeni
repres
one
import
biomed
innov
human
histori
yet
much
remain
learn
vaccin
molecular
basi
attenu
potent
immunogen
still
poorli
understood
consequ
restrict
fundament
understand
human
immun
lav
repres
formid
tool
better
understand
human
immun
respons
regul
could
provid
us
effect
new
way
ration
design
innov
vaccin
immunotherapi
challeng
infecti
diseas
also
treat
human
patholog
cancer
mice
instrument
investig
infecti
cycl
mani
human
pathogen
howev
despit
strong
potenti
applic
lav
research
remain
limit
fundament
preclin
eg
test
lav
candid
level
mostli
due
limit
abil
past
current
model
mount
suffici
strong
accur
immun
respons
highli
immunogen
pathogen
therefor
push
investig
toward
less
relev
mous
costli
logist
challeng
nhp
anim
model
although
mice
never
abl
perfectli
mimic
human
immun
respons
recent
model
improv
demonstr
creat
mice
abl
mount
potent
respons
lav
possibl
futur
effort
direct
toward
gener
mice
mount
potent
polyfunct
immun
respons
tightli
regul
differ
arm
innat
adapt
immun
system
design
object
evalu
model
combin
function
lymphoid
structur
enhanc
human
cytokin
environ
erythromyeloid
physiolog
engraft
addit
humanspecif
immunoregul
liver
microbiota
could
central
endeavor
worth
note
recapitul
establish
persist
memori
b
cell
respons
mice
vaccin
remain
consider
challeng
nevertheless
accur
model
immunolog
event
occur
time
vaccin
activ
adapt
respons
secondari
lymphoid
tissu
seen
reachabl
object
set
event
like
critic
defin
potent
immunogen
success
lav
captur
could
definit
impact
understand
lavinduc
immun
human
immun
overal
